TY - JOUR
T1 - Introducing PIONEER
T2 - a project to harness big data in prostate cancer research
AU - Omar, Muhammad Imran
AU - Roobol, Monique J.
AU - Ribal, Maria J.
AU - Abbott, Thomas
AU - Agapow, Paul Michael
AU - Araujo, Sonia
AU - Asiimwe, Alex
AU - Auffray, Charles
AU - Balaur, Irina
AU - Beyer, Katharina
AU - Bernini, Chiara
AU - Bjartell, Anders
AU - Briganti, Alberto
AU - Butler-Ransohoff, John Edward
AU - Campi, Riccardo
AU - Cavelaars, Marinel
AU - De Meulder, Bertrand
AU - Devecseri, Zsuzsanna
AU - Voss, Marc Dietrich
AU - Dimitropoulos, Konstantinos
AU - Evans-Axelsson, Susan
AU - Franks, Billy
AU - Fullwood, Louise
AU - Horgan, Denis
AU - Smith, Emma Jane
AU - Kiran, Amit
AU - Kivinummi, Kati
AU - Lambrecht, Mark
AU - Lancet, Doron
AU - Lindgren, Peter
AU - MacLennan, Sara
AU - MacLennan, Steven
AU - Nogueira, Maria Manuela
AU - Moen, Fredrik
AU - Moinat, Maxim
AU - Papineni, Kishore
AU - Reich, Christian
AU - Reiche, Kristin
AU - Rogiers, Stijn
AU - Sartini, Claudio
AU - van Bochove, Kees
AU - van Diggelen, Femke
AU - Van Hemelrijck, Mieke
AU - Van Poppel, Hein
AU - Zong, Jihong
AU - N’Dow, James
AU - Andersson, Emelie
AU - Arala, Heidi
AU - Auvinen, Anssi
AU - Willemse, Peter Paul
N1 - Funding Information:
PIONEER will leverage existing valuable clinical prostate cancer datasets by bringing together a complementary group of world-leading clinical, epidemiology, genetics, urology, big data science, health economics and health technology assessment (HTA) research experts, together with patient organizations such as UCAN18 (a urological cancer charity dedicated to providing support to urological cancer patients and their families), europa Uomo19, and the european Alliance for Personalized Medicine14,20. The academic section of the PIONEER consortium includes 32 partners and is coordinated by the European Association of Urology (EAU) and their Guidelines Office, with financial support from the european Commission through the Innovative Medicines Initiative 2 (IMI2)21, complemented by contributions from the pharmaceutical industry and private partners of the European Federation of Pharmaceutical Industry Associations (Supplementary information). In addition, the PIONEER consortium will build on the success and lessons learnt from previous successful IMI projects such as Unbiased Biomarkers in Prediction of Respiratory Disease (U-BIOPRED) and the other components of the Big Data for Better Outcomes Programme (BD4BO) IMI2 framework22(fig. 1).
Funding Information:
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.
AB - Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.
KW - Big Data
KW - Biomedical Research
KW - Humans
KW - Male
KW - Prostatic Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85085488421&partnerID=8YFLogxK
U2 - 10.1038/s41585-020-0324-x
DO - 10.1038/s41585-020-0324-x
M3 - Review article
C2 - 32461687
AN - SCOPUS:85085488421
SN - 1759-4812
VL - 17
SP - 351
EP - 362
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 6
ER -